Literature DB >> 24554659

Loss of a conserved N-linked glycosylation site in the simian immunodeficiency virus envelope glycoprotein V2 region enhances macrophage tropism by increasing CD4-independent cell-to-cell transmission.

Po-Jen Yen1, Alon Herschhorn, Hillel Haim, Ignacio Salas, Christopher Gu, Joseph Sodroski, Dana Gabuzda.   

Abstract

UNLABELLED: Human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) strains differ in their capacity to replicate in macrophages, but mechanisms underlying these differences are not fully understood. Here, we identify a highly conserved N-linked glycosylation site (N173 in SIV, corresponding to N160 in HIV) in the V2 region of the SIV envelope glycoprotein (Env) as a novel determinant of macrophage tropism and characterize mechanisms underlying this phenotype. Loss of the N173 glycosylation site in the non-macrophage-tropic SIVmac239 by introducing an N173Q mutation enhanced viral replication and multinucleated giant cell formation upon infection of rhesus macrophages, while the addition of N173 to SIVmac251 had the opposite effect. The removal of N173 in SIVmac239 enhanced CD4-independent cell-to-cell transmission to CCR5-expressing cells. SIVmac239 with N173Q mediated CD4-independent cell-cell fusion but could not infect CD4-negative cells in single-round infections. Thus, CD4-independent phenotypes were detected only in the context of cell-to-cell contact. Similar results were obtained in SIVmac251 with and without N173. N173 decreased the neutralization sensitivity of SIVmac251 but had no effect on the neutralization sensitivity of SIVmac239. The N173Q mutation had no effect on SIVmac239 binding to CD4 in Biacore assays, coimmunoprecipitation assays, and enzyme-linked immunosorbent assays (ELISAs). These findings suggest that the loss of the N173 N-linked glycosylation site increases SIVmac239 replication in macrophages by enhancing CD4-independent cell-to-cell virus transmission through CCR5-mediated fusion. This mechanism may facilitate the escape of macrophage-tropic viruses from neutralizing antibodies while promoting spreading infection by these viruses in vivo. IMPORTANCE: In this study, we identify a genetic determinant in the viral envelope (N173) that increases replication and spreading infection of SIV strains in macrophages by enhancing cell-to-cell virus transmission. This effect is explained by a novel mechanism involving increased cell-to-cell fusion in the absence of CD4, the primary receptor that normally mediates virus entry. The same genetic determinant also affects the sensitivity of these viruses to inhibition by neutralizing antibodies. Most macrophage-tropic HIV/SIV strains are known to be neutralization sensitive. Together, these findings suggest that this efficient mode of virus transmission may facilitate the escape of macrophage-tropic viruses from neutralizing antibodies while promoting spreading infection by these viruses to cells expressing little or no CD4 in vivo.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24554659      PMCID: PMC3993815          DOI: 10.1128/JVI.02785-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  101 in total

1.  The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1.

Authors:  Claudia Cicala; Elena Martinelli; Jonathan P McNally; Diana J Goode; Ravindra Gopaul; Joseph Hiatt; Katija Jelicic; Shyamasundaran Kottilil; Katilyn Macleod; Angeline O'Shea; Nikita Patel; Donald Van Ryk; Danlan Wei; Massimiliano Pascuccio; Ling Yi; Lyle McKinnon; Preson Izulla; Joshua Kimani; Rupert Kaul; Anthony S Fauci; James Arthos
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-20       Impact factor: 11.205

2.  Molecular architecture of native HIV-1 gp120 trimers.

Authors:  Jun Liu; Alberto Bartesaghi; Mario J Borgnia; Guillermo Sapiro; Sriram Subramaniam
Journal:  Nature       Date:  2008-07-30       Impact factor: 49.962

3.  Efficient HIV-1 transmission from macrophages to T cells across transient virological synapses.

Authors:  Fedde Groot; Sonja Welsch; Quentin J Sattentau
Journal:  Blood       Date:  2008-02-22       Impact factor: 22.113

4.  A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains.

Authors:  Samantha H Johnston; Michael A Lobritz; Sandra Nguyen; Kara Lassen; Shirley Delair; Filippo Posta; Yvonne J Bryson; Eric J Arts; Tom Chou; Benhur Lee
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

5.  Partial inhibition of human immunodeficiency virus replication by type I interferons: impact of cell-to-cell viral transfer.

Authors:  Daniela Vendrame; Marion Sourisseau; Virginie Perrin; Olivier Schwartz; Fabrizio Mammano
Journal:  J Virol       Date:  2009-08-12       Impact factor: 5.103

6.  Quantitative analysis of the interactions between HIV-1 integrase and retroviral reverse transcriptases.

Authors:  Alon Herschhorn; Iris Oz-Gleenberg; Amnon Hizi
Journal:  Biochem J       Date:  2008-05-15       Impact factor: 3.857

7.  Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Authors:  Laura M Walker; Sanjay K Phogat; Po-Ying Chan-Hui; Denise Wagner; Pham Phung; Julie L Goss; Terri Wrin; Melissa D Simek; Steven Fling; Jennifer L Mitcham; Jennifer K Lehrman; Frances H Priddy; Ole A Olsen; Steven M Frey; Phillip W Hammond; Stephen Kaminsky; Timothy Zamb; Matthew Moyle; Wayne C Koff; Pascal Poignard; Dennis R Burton
Journal:  Science       Date:  2009-09-03       Impact factor: 47.728

8.  Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1.

Authors:  Brandon F Keele; Hui Li; Gerald H Learn; Peter Hraber; Elena E Giorgi; Truman Grayson; Chuanxi Sun; Yalu Chen; Wendy W Yeh; Norman L Letvin; John R Mascola; Gary J Nabel; Barton F Haynes; Tanmoy Bhattacharya; Alan S Perelson; Bette T Korber; Beatrice H Hahn; George M Shaw
Journal:  J Exp Med       Date:  2009-05-04       Impact factor: 14.307

9.  Enhanced macrophage tropism of HIV in brain and lymphoid tissues is associated with sensitivity to the broadly neutralizing CD4 binding site antibody b12.

Authors:  Rebecca L Dunfee; Elaine R Thomas; Dana Gabuzda
Journal:  Retrovirology       Date:  2009-07-20       Impact factor: 4.602

Review 10.  The achilles heel of the trojan horse model of HIV-1 trans-infection.

Authors:  Marielle Cavrois; Jason Neidleman; Warner C Greene
Journal:  PLoS Pathog       Date:  2008-06-27       Impact factor: 6.823

View more
  10 in total

1.  Slow Receptor Binding of the Noncytopathic HIV-2UC1 Envs Is Balanced by Long-Lived Activation State and Efficient Fusion Activity.

Authors:  Miranda Harris; Sneha Ratnapriya; Angela Chov; Héctor Cervera; Alisha Block; Christopher Gu; Nathaniel Talledge; Louis M Mansky; Joseph Sodroski; Alon Herschhorn
Journal:  Cell Rep       Date:  2020-06-09       Impact factor: 9.423

2.  Identification and characterization of a macrophage-tropic SIV envelope glycoprotein variant in blood from early infection in SIVmac251-infected macaques.

Authors:  Po-Jen Yen; Megan E Mefford; James A Hoxie; Kenneth C Williams; Ronald C Desrosiers; Dana Gabuzda
Journal:  Virology       Date:  2014-05-08       Impact factor: 3.616

3.  HIV-1 envelope glycan moieties modulate HIV-1 transmission.

Authors:  Ruizhong Shen; Milan Raska; Diane Bimczok; Jan Novak; Phillip D Smith
Journal:  J Virol       Date:  2014-10-01       Impact factor: 5.103

4.  Bioinformatic analysis of neurotropic HIV envelope sequences identifies polymorphisms in the gp120 bridging sheet that increase macrophage-tropism through enhanced interactions with CCR5.

Authors:  Megan E Mefford; Kevin Kunstman; Steven M Wolinsky; Dana Gabuzda
Journal:  Virology       Date:  2015-03-20       Impact factor: 3.616

5.  Tissue-resident macrophages can contain replication-competent virus in antiretroviral-naive, SIV-infected Asian macaques.

Authors:  Sarah R DiNapoli; Alexandra M Ortiz; Fan Wu; Kenta Matsuda; Homer L Twigg; Vanessa M Hirsch; Kenneth Knox; Jason M Brenchley
Journal:  JCI Insight       Date:  2017-02-23

6.  A cellular trafficking signal in the SIV envelope protein cytoplasmic domain is strongly selected for in pathogenic infection.

Authors:  Scott P Lawrence; Samra E Elser; Workineh Torben; Robert V Blair; Bapi Pahar; Pyone P Aye; Faith Schiro; Dawn Szeltner; Lara A Doyle-Meyers; Beth S Haggarty; Andrea P O Jordan; Josephine Romano; George J Leslie; Xavier Alvarez; David H O'Connor; Roger W Wiseman; Christine M Fennessey; Yuan Li; Michael Piatak; Jeffrey D Lifson; Celia C LaBranche; Andrew A Lackner; Brandon F Keele; Nicholas J Maness; Mark Marsh; James A Hoxie
Journal:  PLoS Pathog       Date:  2022-06-17       Impact factor: 7.464

7.  Derivation and Characterization of a CD4-Independent, Non-CD4-Tropic Simian Immunodeficiency Virus.

Authors:  Adrienne E Swanstrom; Beth Haggarty; Andrea P O Jordan; Josephine Romano; George J Leslie; Pyone P Aye; Preston A Marx; Andrew A Lackner; Gregory Q Del Prete; James E Robinson; Michael R Betts; David C Montefiori; Celia C LaBranche; James A Hoxie
Journal:  J Virol       Date:  2016-04-29       Impact factor: 5.103

Review 8.  V2-Specific Antibodies in HIV-1 Vaccine Research and Natural Infection: Controllers or Surrogate Markers.

Authors:  Ralf Duerr; Miroslaw K Gorny
Journal:  Vaccines (Basel)       Date:  2019-08-06

9.  Concomitant Enhancement of HIV-1 Replication Potential and Neutralization-Resistance in Concert With Three Adaptive Mutations in Env V1/C2/C4 Domains.

Authors:  Naoya Doi; Masaru Yokoyama; Takaaki Koma; Osamu Kotani; Hironori Sato; Akio Adachi; Masako Nomaguchi
Journal:  Front Microbiol       Date:  2019-01-17       Impact factor: 5.640

10.  Identification of HIV-1 Envelope Mutations that Enhance Entry Using Macaque CD4 and CCR5.

Authors:  Jeremy I Roop; Noah A Cassidy; Adam S Dingens; Jesse D Bloom; Julie Overbaugh
Journal:  Viruses       Date:  2020-02-21       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.